The University of Oklahoma

Other

The United States Government As Represented by the Department of Veterans Affairs

Oregon Health & Science University

William H Hildebrand

David Lewinsohn

Curtis McMurtrey

Melanie Harriff

Deborah Lewinsohn

Aaron Nilsen

R Scott Duthie

Haihong Jin

Erin Adams

Cara Froyd

Rico Buchli

Heather D Hickman

Kiley R Prilliman

Mary Ellexson

Pierre Chretien

Steven Cate

Heather Hickman

Curtis Mcmurtrey

Compositions that include one isolated, class I HLA-E trimolecular complex that includes a peptide ligand unique to-infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three components are also disclosed.

Compositions comprising soluble HLA/M. tuberculosis-specific ligand complexes and methods of production and use thereof

Disclosed are small molecules and pharmaceutical compositions comprising them that can be used in treating diseases associated with the major histocompatibility complex (MHC) molecule MR1.

Small molecules that bind MR1

The present invention relates generally to a methodology for assaying the binding of a peptide to an individual, specific, soluble HLA molecule using fluorescence polarization. The peptides utilized in the method may be identified by indirect methods utilizing T lymphocytes, or by a direct method of epitope discovery described herein.

Epitope testing using soluble HLA

The present invention relates generally to a methodology for the isolation, purification and identification of peptide ligands presented by MHC positive cells. In particular, the methodology of the present invention relates to the isolation, purification and identification of these peptide ligands from soluble class I and class II MHC molecules which may be uninfected, infected, or tumorgenic. The methodology of the present invention broadly allows for these peptide ligands and their comcomittant source proteins thereof to be identified and used as markers for infected versus uninfected cells and/or tumorgenic versus nontumorgenic cells with said identification being useful for marking or targeting a cell for therapeutic treatment or priming the immune response against infected cells.

Comparative ligand mapping from MHC positive cells

The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.

Method and apparatus for the production of soluble MHC antigens and uses thereof

There is provided a method for directly typing or sequencing HLA-A, -B, or -C alleles from a tissue sample wherein exons 2 and 3 of the HLA-A, -B, or -C alleles from the sample are amplified together in a locus specific manner and then separated out and individually amplified in a locus specific manner. After the two amplifications, the amplified exons are directly sequenced, the sequences are recombined, and a comparison is made between the derived HLA allele sequence and an HLA allele database, thereby giving an exact HLA-A, -B, or -C type for the sample being tested.

Class I sequence based typing of HLA-A, -B, and -C alleles by direct DNA sequencing

Growing community of inventors

Edmond, OK, United States of America

William H Hildebrand